Health Care • Biotechnology: Pharmaceutical Preparations
$0.37 ▼ -0.01
(-1.55%)
MKT CAP: $8.0M • VOL: 36.8K
52W L $0 52W H $2
ROARABLE / RQD
D • 44/100
PIOTROSKI
2 / 9
SNGX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $119.4K | $839.4K |
| YoY Revenue Growth % | — | -85.8% | — |
| Gross Profit | — | $0 | — |
| Gross Margin % | — | 0.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$11.8M | -$9.4M | -$7.7M |
| Operating Margin % | — | -80.0% | -80.0% |
| Net Income (GAAP) | -$11.1M | -$8.3M | -$6.1M |
| EBITDA (Normalized) | -$11.8M | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$10.3M | -$8.4M | -$8.6M |
| Capital Expenditures (CapEx) | $5.9K | — | — |
| Free Cash Flow (FCF) | -$10.3M | -$8.4M | -$8.6M |
| FCF Margin % | — | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | — | — | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $5.3M | $4.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SNGX.